Description
65IB 42-2A PRODUCT ADDITION - NEW PACKAGE SIZE (NPS) - INDEPENDENT FEDERAL CEILING PRICE (FCP) - DUAL PRICING
Base award description: 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2026-08-07+$0= $0
- Mod P000012026-09-02+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2026-08-07 | +$0 | $0 | 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS, FSS CONTRACT AWARD |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2026-09-02 | +$0 | $0 | 65IB 42-2A PRODUCT ADDITION - NEW PACKAGE SIZE (NPS) - INDEPENDENT FEDERAL CEILING PRICE (FCP) - DUAL PRICING |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI DDEVYUAXJ624)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526N0840 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $19,139 | FY2026 |
| 36E79726A0023 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
| 36C24526N0835 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $34,605 | FY2026 |
| 36C26026P0420 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $107,540 | FY2026 |
| 36C26126P0581 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $27,250 | FY2026 |
| 36C26126N0358 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
Other recipients under 6505 from NAC FEDERAL SUPPLY SCHEDULE (36F797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36F79726D058E | REVOLUTION MEDICINES, INC. | NAC FEDERAL SUPPLY SCHEDULE (36F797) | $0 | FY2026 |
| 36F79726D0172 | LUNDBECK LLC | NAC FEDERAL SUPPLY SCHEDULE (36F797) | $0 | FY2026 |
| 36F79726D0195 | MILESTONE PHARMACEUTICALS USA, INC. | NAC FEDERAL SUPPLY SCHEDULE (36F797) | $0 | FY2026 |
| 36F79726D0165 | RECKITT BENCKISER LLC | NAC FEDERAL SUPPLY SCHEDULE (36F797) | $0 | FY2026 |
| 36F79726D0118 | OMEROS CORPORATION | NAC FEDERAL SUPPLY SCHEDULE (36F797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36F79726D0181_3600 · retrieved 2026-09-26.